Skip to content

A Study of the Impact of Different Delivery Modes on Specific Macronutrient Components in Human Milk

A Study of the Impact of Different Delivery Modes on Specific Macronutrient Components in Human Milk

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05516940
Acronym
ZoomMING
Enrollment
250
Registered
2022-08-26
Start date
2022-05-06
Completion date
2023-07-30
Last updated
2025-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

The aim of the study is to evaluate the impact of different delivery modes on specific macronutrient components in human milk.

Detailed description

The main objective of the study is to explore the differences in human milk composition from mothers delivering by Caesarean-section and normal vaginal deliveries. To further associate the differences found in human milk composition to infant outcomes.

Interventions

None listed

Sponsors

Chinese Center for Disease Control and Prevention, National Institute for Nutrition and Health
CollaboratorUNKNOWN
SAS Institute
CollaboratorINDUSTRY
Veeva Systems
CollaboratorINDUSTRY
Société des Produits Nestlé (SPN)
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
Yes

Inclusion criteria

1. Human milk to be selected from the mothers who have delivered at full term (\>37 weeks of gestation). 2. 125 subjects will be selected who have delivered infants by Caesarean-section. 3. 125 subjects will be selected who have delivered infants by vaginal/normal deliveries. 4. Subjects will be selected based on sample availability. 5. Based on sample availability to balance by stage of lactation, geographical locations within China. 6. Subjects of Han ethnicity. 7. The collection of existing biological material and/or health-related personal data have been consented in the frame of the approved original study scope. We will propose to the participants to consent to this specific research.

Exclusion criteria

1\) Incomplete information either for the subject or the sample collected.

Design outcomes

Primary

MeasureTime frameDescription
Differences in HMO from mothers' milk who delivered by Caesarean-section and normal vaginal deliveries.baseline (no primary mothers' milk collection, but from existing human milk samples)HMO will be analyzed by HPLC-FLD

Secondary

MeasureTime frameDescription
Differences in human milk fat from mothers who delivered by Caesarean-section and normal vaginal deliveries.baseline (no primary collection, but from existing human milk samples)Fatty acid will be analyzed by GC-FID
Differences in human milk proteins from mothers who delivered by Caesarean-section and normal vaginal deliveries.baseline (no primary collection, but from existing human milk samples)Proteins will be analyzed by Ultra-high phase liquid chromatography
Differences in human milk gangliosides from mothers who delivered by Caesarean-section and normal vaginal deliveries.baseline (no primary collection, but from existing human milk samples)gangliosides will be analyzed by GC-MS
Association of the differences in human milk composition with subject-reported outcomesbaseline (no primary collection, but from the existing questionnaires)The subject-reported outcomes were existing information in the questionnaires

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026